| First Author | Srivastava R | Year | 2023 |
| Journal | Antib Ther | Volume | 6 |
| Issue | 4 | Pages | 253-264 |
| PubMed ID | 38075240 | Mgi Jnum | J:354609 |
| Mgi Id | MGI:7663317 | Doi | 10.1093/abt/tbad021 |
| Citation | Srivastava R, et al. (2023) Development of a human glioblastoma model using humanized DRAG mice for immunotherapy. Antib Ther 6(4):253-264 |
| abstractText | Glioblastoma (GBM) is the most common and lethal primary brain tumor. The development of alternative humanized mouse models with fully functional human immune cells will potentially accelerate the progress of GBM immunotherapy. We successfully generated humanized DRAG (NOD.Rag1KO.IL2RgammacKO) mouse model by transplantation of human DR4(+) hematopoietic stem cells (hHSCs), and effectively grafted GBM patient-derived tumorsphere cells to form xenografted tumors intracranially. The engrafted tumors recapitulated the pathological features and the immune cell composition of human GBM. Administration of anti-human PD-1 antibodies in these tumor-bearing humanized DRAG mice decreased the major tumor-infiltrating immunosuppressive cell populations, including CD4(+)PD-1(+) and CD8(+)PD-1(+) T cells, CD11b(+)CD14(+)HLA-DR(+) macrophages, CD11b(+)CD14(+)HLA-DR(-)CD15(-) and CD11b(+)CD14(-)CD15(+) myeloid-derived suppressor cells, indicating the humanized DRAG mice as a useful model to test the efficacy of GBM immunotherapy. Taken together, these results suggest that the humanized DRAG mouse model is a reliable preclinical platform for studying brain cancer immunotherapy and beyond. |
